Beacon Therapeutics (USA), Inc.

Beacon Therapeutics (USA), Inc., a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in phase 1/2 clinical trials; and achromatopsia that is in phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. Beacon Therapeutics (USA), Inc. was formerly known as Applied Genetic Technologies Corporation and changed its name to Beacon Therapeutics (USA), Inc. in March 2023. The company was founded in 1999 and is based in Alachua, Florida with an additional location in Cambridge, Massachusetts and London, United Kingdom.